SB
VTGN icon

Samsara BioCapital’s VistaGen Therapeutics VTGN Stock Holding History

Samsara BioCapital’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,288
Closed -$606K – 61
2022
Q1 		$606K Hold
16,288
– – 0.15% 52
2021
Q4 		$953K Hold
16,288
– – 0.18% 45
2021
Q3 		$1.34M Sell
16,288
-8,132
-33% -$707K 0.21% 44
2021
Q2 		$2.31M Sell
24,420
-36,630
-60% -$2.71M 0.28% 42
2021
Q1 		$3.9M Buy
61,050
+6,371
+12% +$425K 0.72% 32
2020
Q4 		$3.18K Buy
+54,679
New +$1.4M 0.32% 30

Other funds holding VTGN

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Samsara BioCapital's VTGN Position: Q2 2022 in Review

Samsara BioCapital sold out of VistaGen Therapeutics (VTGN) in Q2 2022, closing a stake of 16,288 shares — an estimated $606K sold.

Samsara BioCapital first reported a position in VTGN in Q4 2020 and held it in 6 quarters. The position peaked at $3.9M in Q1 2021. 112 funds tracked by Wall St. Rank hold VTGN as of Q2 2022.

  • Samsara BioCapital reported no remaining VistaGen Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Samsara BioCapital sold 16,288 VistaGen Therapeutics shares in Q2 2022, an estimated $606K.
  • Samsara BioCapital first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 6 quarters.
  • Samsara BioCapital's VistaGen Therapeutics position peaked at $3.9M in Q1 2021.
  • 112 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2022.

Based on Samsara BioCapital's 13F filing for Q2 2022, filed 15 Aug 2022.